Therapeutics (Industry)

(T 3) TRPM8 Channel Blockade with Elismetrep in a Phase 2B study: A Novel Approach for Treating Migraine

(T 5) Weight Loss With Atogepant Versus Topiramate: Post hoc Analysis of the Head-to-Head TEMPLE Trial

(T 6) In vitro Profile of Elismetrep: A Potent and Highly Selective Blocker of the Migraine-Associated Channel TRPM8

(T 7) The Impact of Ubrogepant on the Use of Other Migraine Acute Treatments, Opioid Discontinuation, and Healthcare Utilization: Results from a Pre-Post Opioid Subcohort Analysis

(T 8) Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Children and Adolescents: Safety Outcomes From the SPACE Program

(T 9) Time course of rimegepant efficacy for the prevention of episodic migraine in a phase 4 trial enrolling participants with prior inadequate responses to 2 to 4 categories of non-migraine-specific oral preventive medications

(T 01) Efficacy of celecoxib oral solution in the acute treatment of patients with morning migraine: a post-hoc subgroup analysis of Study 006 and 007

(T 02) Long-Term Safety, Tolerability, and Efficacy of Atogepant for the Preventive Treatment of Migraine: Final Results from a Phase 3, Open-Label, 156-Week, Long-Term Safety Extension Study

(T 04) Patient Treatment Satisfaction With OnabotulinumtoxinA Versus Topiramate for Chronic Migraine

(T 10) Safety and Tolerability of Anti-PACAP Monoclonal Antibody Lu AG09222 when Co-administered with a Gepant in Participants with Migraine

(T 11) Effect of Adding Atogepant to OnabotulinumtoxinA on Symptoms-Free Days: Results from a Phase 3, Multicenter, 24-Week Open-Label Study (UNCHAINED)

(T 12) Treatment Patterns, Medication Usage, Effectiveness, and Safety Among Veterans Treating with Remote Electrical Neuromodulation (REN)

(T 13) Blood Pressure Changes With Atogepant in Overweight and Obese Persons With Migraine and Baseline Hypertension: Interim Analysis of a Phase 3, Multicenter, Open-label, 156-Week Extension Study

(T 14) Characterizing Menstrual Migraine: Multi-Country Results from the Chronic Migraine Epidemiology and Outcomes-International (CaMEO-I) Study

(T 15) Real-World Impact of Eptinezumab Treatment on Migraine-Related Cognitive Symptoms in Participants in Whom ≥1 Prior CGRP-Targeted Therapy had Failed: 12-Month Results of a Prospective Study

(T 16) Establishing Structural and Functional Comparability Between ABP 450 and OnabotulinumtoxinA to Support Biosimilarity

(T 17) Dose escalation to eptinezumab 300 mg: A subgroup analysis of the 60-week, open-label SUNSET trial in Japanese participants with chronic migraine who experienced suboptimal response

(T 18) Treatment outcomes with rimegepant versus other standard of care acute migraine medications in the observational CONFIDENCE study

(T 19) Symbravo® (MoSEIC(TM) meloxicam and rizatriptan) for the Acute Treatment of Migraine: Post-hoc Composite Efficacy and Return to Function Endpoint Analysis from MOMENTUM

(T 22) Rimegepant for the Preventive Treatment of Migraine: A Phase 3, Randomized, Double-blind, Placebo-controlled Study in Adults from China

(T 23) Safety, tolerability, and pharmacokinetics of PRT-064040 nasal spray following single and multiple ascending doses in healthy adults: a phase 1 study

(T 24) Comparative Efficacy of Symbravo® vs. Gepants for Acute Treatment of Migraine: A Network Meta-Analysis

(T 25) Consistency of Ubrogepant for the Acute Treatment of Migraine Across Consecutive Migraine Attacks: Results from a 52-Week Long-Term Extension Trial

(T 26) Consistent efficacy of eptinezumab across countries in adults with CM and MOH who also received patient education: Results from the RESOLUTION trial

(T 27) Pharmacokinetics and Safety of ASY202 for the Treatment of Acute Migraine Disease

(T 28) Effectiveness of Remote Electrical Neuromodulation (REN) Wearable for Migraine Prevention in Reducing Attack Duration and Frequency: A Real-World Study

(T 29) Headache hours with severe pain intensity during long-term treatment with eptinezumab: Post hoc analysis of the DELIVER trial

(T 30) Symbravo® (MoSEIC(TM) Meloxicam and Rizatriptan) for the Treatment of Migraine: Sustained Pain Relief and Pain Freedom Among 2-Hour Responders in the Phase 3 MOMENTUM and MOVEMENT Trials

(T 32) A phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of zavegepant for the acute treatment of migraine in Asian adults

(T 33) Symbravo® (MoSEIC(TM) meloxicam and rizatriptan) for the Acute Treatment of Migraine: Post-hoc Composite Efficacy and Safety Endpoint Analysis of INTERCEPT and MOMENTUM

(T 34) The human pharmacokinetics of elismetrep, a TRPM8 migraine-associated channel blocker (MACB), are well-suited for a migraine therapeutic

(T 35) Pharmacokinetic comparison of STS101 (Nasal DHE nasal powder) with liquid nasal spray, and injectable DHE formulations

(T 38) Feasibility of Middle Meningeal Artery Embolization with n-Butyl Cyanoacrylate for Refractory Chronic Migraine: MIGRAINE Study Preliminary Results

(T 39) Comparison of FDA approved intranasal acute migraine treatment adverse event profiles

(T 94) Efficacy and safety of zavegepant for the acute treatment of migraine: pooled analysis of two phase 3 randomized controlled trials